Semper Paratus Acquisition Corporation

Semper Paratus Acquisition Corporation

LGSTW
Semper Paratus Acquisition CorporationUS flagNASDAQ Global Market
0.06
USD
+0.02
- -
949,432.00Market Cap
Semper Paratus Acquisition Corporation
LGSTW
(NASDAQ Global Market)

Recent

price

0.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available
Business
Semper Paratus Acquisition Corporation (LGSTW) is a special purpose acquisition company formed to effect a merger, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting opportunities in the transportation, supply chain, and logistics industries; it offers no current products or operational services beyond holding proceeds in trust for deployment post-combination. Incorporated in 2021 as a Cayman Islands exempted company with principal headquarters in New York, New York, the firm maintains a lean structure focused on identifying targets across any stage of corporate evolution, leveraging its management's expertise in aviation, logistics restructuring, and supply chain optimization. In early 2024, shareholders approved and completed a reverse merger business combination with Tevogen Bio Inc., a clinical-stage biotechnology company developing T-cell therapies and AI-driven immunotherapies, resulting in the combined entity's domestication to Delaware, name change to Tevogen Bio Holdings Inc., and listing under new tickers, with approximately 99.8% of shares redeemed leading to about $15.9 million distributed from trust; LGSTW warrants persist as legacy securities traded on Nasdaq post-transaction.